

## Anne-Grethe Mortensen joins TargED Biopharmaceuticals as Non-Executive Board Member

November 14<sup>th</sup>, 2024  
Utrecht, the Netherlands

TargED Biopharmaceuticals B.V., a Dutch biotech company that develops targeted biological drugs to improve the treatment of thrombosis and thrombosis related diseases, is pleased to announce the appointment of Anne-Grethe Mortensen to its Board of Directors as a Non-Executive Board Member. With over 35 years of experience in pharmaceutical leadership, Mortensen brings extensive strategic and operational expertise that will play a vital role in guiding TargED's growth and mission to address critical medical needs through innovative therapeutics.

Anne-Grethe Mortensen joins TargED following a distinguished career at Bayer Pharma AG, where she held several senior executive positions, including her most recent role as Chief Marketing Officer and Senior Executive Vice President. During her tenure at Bayer, she led successful commercial strategies across a range of therapeutic areas, including Cardiovascular, Hematology, Ophthalmology and Women's Health. She played a key role in driving global brand growth, leading cross-functional teams, and successfully launching medicines that have improved patient outcomes worldwide.

"Anne-Grethe's appointment is an exceptional addition to TargED's board," said Kristof Vercruyssen, CEO of TargED Biopharmaceuticals. "Her extensive background in pharmaceutical marketing and leadership, and her commitment to advancing patient-centric solutions, align perfectly with TargED's mission. We are confident that her insights will be invaluable as we advance our lead compound, TGD001."

In her role as Non-Executive Board Member, Mortensen will leverage her industry knowledge and strategic expertise to support TargED's mission of advancing its lead compound to maximize therapeutic impact for patients. Mortensen added, "I am excited to support TargED's mission and look forward to contributing to the development of its promising therapeutic approach."

### About TargED Biopharmaceuticals

TargED Biopharmaceuticals B.V. is a Netherlands based biotechnology company developing first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using single-chain antibodies ("VhH") to deliver enzymes to sites of thrombosis, enabling 'targeted' thrombolysis. The company's lead compound, TGD001, is currently in development for the treatment of thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

Founded in July 2020 as a spin-off from the University Medical Center Utrecht, TargED has raised over €45 million in funding to support its growth to become a clinical-stage company.

For more information, please visit [www.targedbio.com](http://www.targedbio.com)

Contact: [info@targedbio.com](mailto:info@targedbio.com)